You are here

Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing products and treatments that will benefit patients around the world. And from specialized efforts in biosimilars and rare disease to oncology and vaccines, we are committed to developing medical solutions that will matter most to the people we serve.?

Key Innovative Programs in Registration / Phase 3

Key Biosimilars Programs in Registration / Phase 3

Key Programs in Phase 2

Pipeline date and pdf

Pipeline Snapshot as of January 29, 2019

  • Discovery Projects
  • Phase 1
    35
  • Phase 2
    28
  • Phase 3
    26
  • Registration
    11
  • Total100
 
Compound Name
Indication
Phase
Submission Type
Compound Type
PF-06928316
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Respiratory Syncytial Virus Infection Phase 1 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections (BREAKTHROUGH)
Project advanced
Phase 3 New Molecular Entity Vaccine
PF-06886992
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Serogroups ABCWY meningococcal infections Phase 1 New Molecular Entity Vaccine
PF-06753512
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Prostate Cancer Phase 1 New Molecular Entity Vaccine
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridium difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06936308
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Therapeutic Vaccine
Go to clinical trial
Multiple Cancers
Project advanced
Phase 1 New Molecular Entity Vaccine
PF-06842433
Therapeutic Area:
Vaccines
Phase:Phase 2
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and non-invasive Pneumococcal infections Phase 2 New Molecular Entity Vaccine
PF-06760805
Therapeutic Area:
Vaccines
Phase:Phase 1
Compound Type:Vaccine
Business Segment:
WRD
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive Group B streptococcus infection Phase 1 New Molecular Entity Vaccine
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ talazoparib (MDV3800) for: Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors (Biologic) Phase 2 Product Enhancement Biologic
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ PF-04518600 (OX40) for: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 2 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) (BREAKTHROUGH) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Gastric Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ PF-04518600 (OX40) and PF-05082566 (4-1BB) for: Cancer (Biologic) Phase 1 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Medicines
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Combo w/ talazoparib (MDV3800) and Array's MEK inhibitor for: Solid Tumors (Biologic) Phase 1 Product Enhancement Biologic